NCT01462851 - A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions

Healthy

Interventions

DRUG

PF-05297909 25 mg

Single oral (PO) dose, PF-05297909 25 mg

DRUG

PF-05297909 100 mg

Single oral (PO) dose, PF-05297909 100 mg

DRUG

PF-05297909 250 mg

Single oral (PO) dose, PF-05297909 250 mg

DRUG

PF-05297909 525 mg

Single oral (PO) dose, PF-05297909 525 mg

DRUG

PF-05297909 525 mg

Single oral (PO) dose, 525 mg

Trial Locations (2)

Pfizer Investigational Site, Glendale

Pfizer Investigational Site, New Haven